You are viewing the site in preview mode
Skip to main content
| |
Number of eyes
|
Eyes with SE-IOP
|
Eye-year incidence, % (95% CI)
|
p-value
|
|---|
|
Non-switched patients
|
|
Bevacizumab
|
|
Treated eye
|
71
|
3
|
3.17 (0.65; 9.26)
|
0.69
|
|
Fellow eye
|
71
|
2
|
2.11 (0.26; 7.63)
|
ref
|
|
Switched patients
|
|
Bevacizumab
|
|
Treated eye
|
49
|
2
|
3.09 (0.37; 11.18)
|
0.46
|
|
Fellow eye
|
49
|
4
|
6.17 (1.68; 15.79)
|
ref
|
|
Aflibercept
|
|
Treated eye
|
49
|
1
|
1.07 (0.03; 5.98)
|
0.37
|
|
Fellow eye
|
49
|
3
|
3.28 (0.68; 9.57)
|
ref
|
|
All study groups
|
|
Treated eye
|
169
|
6
|
2.38 (0.87; 5.17)
|
0.45
|
|
Fellow eye
|
169
|
9
|
3.58 (1.64; 6.8)
|
ref
|
